Sino-Biocan has recently completed a Series A round of funding

Sino-Biocan(Beijing) Biotech Ltd(hereinafter referred to as “Sino-Biocan”) has recently completed a Series A round of funding of nearly RMB 100 million,led by Grand Flight Investment and continued by its long-time shareholder, Sinovation Ventures.This round of financing will be used to expand the new R&D and design institute (including R&D centre, design centre, testing centre, data centre, customer service centre and after-sales service centre) and expand the R&D pipeline, further build and improve the capacity management of fully automated equipment, GMP-grade disposables, GMP and clinical test-grade liquid production at Shanghai production base. We are also improving technical service for existing products and cell preparation tools. We aim to develop a multi-marketing approach to meet the demand of recent rapid growth in original product development for multiple pipelines of differentiated cellular and genetic drugs, in line with accelerated drug declaration and orderly capacity expansion and meet the needs of a wide range of GMP-grade cell preparation markets.